Table 2.
Distribution of 5-HT2A, TPH1 and GNB3 gene polymorphisms in the study population.
| 5-HT2A | TPH1 | GNB3 | ||||||||
| CC | CT | TT | CC | CA | AA | CC | CT | TT | ||
| Patients | responders (n = 43) | 17 (39.5) | 23 (53.5) | 3 (7.0) | 14 (32.6) | 14 (32.6)2 | 15 (34.8) | 18 (41.9) | 20 (46.5) | 5 (11.6) |
| females | 9 (34.6) | 14 (53.8) | 3 (11.5) | 8 (30.8) | 9 (34.6) | 9 (34.6) | 14 (53.9) | 7 (26.9) | 5 (19.2) | |
| males | 8 (47.1) | 9 (52.9) | 0 (0.0) | 6 (35.3) | 5 (29.4) | 6 (35.3) | 4 (23.5) | 13 (76.5)3 | 0 (0.0) | |
| Patients | non-responders (n = 51) | 27 (54.0) | 19 (38.0) | 4 (8.0) | 12 (23.5) | 28 (54.9) | 11 (21.6) | 27 (53.0) | 22 (43.1) | 2 (3.9) |
| females | 16 (76.2)1 | 4 (19.0) | 1 (4.8) | 3 (13.6) | 13 (59.1) | 6 (27.3) | 13 (59.1) | 8 (36.4) | 1 (4.5) | |
| males | 11 (37.9) | 15 (51.7) | 3 (10.3) | 9 (31.0) | 15 (51.7) | 5 (17.3) | 14 (48.3) | 14 (48.3) | 1 (3.4) | |
| Controls | (n = 392) | 166 (43.0) | 176 (45.6) | 44 (11.4) | 106 (27.0) | 205 (52.3) | 81 (20.7) | 218 (55.6) | 144 (36.7) | 30 (7.7) |
| females | 77 (43.5) | 81 (45.8) | 19 (10.7) | 42 (23.3) | 90 (50.0) | 48 (26.7) | 107 (59.5) | 60 (33.3) | 13 (7.2) | |
| males | 89 (42.6) | 95 (45.4) | 25 (12.0) | 64 (30.2) | 115 (54.2) | 33 (15.6) | 111 (52.4) | 84 (39.6) | 17 (8.0) | |
Statistics: 1 p = 0.005, OR = 6.04 (95% Cl 1.67–21.93) compared to responders; p = 0.005, OR = 4.16 (95% CI 1.46–11.84) compared to controls
2 p = 0.030, OR = 0.59 (95% Cl 0.36–0.98) compared to non-responders; p = 0.016, OR = 0.44 (95% CI 0.23–0.86) compared to controls
3 p = 0.061, OR = 3.48 (95% Cl 0.92–13.25) compared to non-responders; p = 0.004, OR = 4.95 (95% CI 1.56–15.70) compared to controls
Abbreviations: 5-HT2A: serotonin 2A receptor gene; TPH1: tryptophan hydroxylase 1 gene, GNB3: G-protein beta-3 subunit gene.